A pilot, longitudinal, 24-week study to evaluate the effect of interferon beta-1a subcutaneous on changes in susceptibility-weighted imaging-filtered phase assessment of lesions and subcortical deep-gray matter in relapsing-remitting multiple sclerosis

Authors
Category Primary study
JournalTherapeutic Advances in Neurological Disorders
Year 2015
This article has no abstract
Epistemonikos ID: 462ed6a3ad9093a9a8c7e130af719419615be5d9
First added on: Mar 31, 2022